What Kanjinti Treats: Main Uses and Benefits

Kanjinti is used to manage specific types of cancer. Its clinical use contributes to easing the overall symptom load by supporting disease control, and is applied based on the stage and location of the cancer.

Kanjinti is relevant for use in the following areas:

Primary Indications and Therapeutic Benefit

This medicine is commonly used across conditions presenting with acute or disruptive symptom patterns, in patients whose tumors meet the specific clinical criteria, specifically for breast cancer (in various stages) and advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The therapeutic benefit provided is centered on supporting the management of the underlying condition.

In early-stage disease, Kanjinti may be part of symptomatic management in the adjuvant setting to contribute to easing the overall symptom load associated with potential recurrence. It is also used in the neoadjuvant setting, where its use is applied in addressing the functional stability associated with the tumor.

In advanced or metastatic disease, the medicine is applied during phases where symptoms become more noticeable. The goal in these situations is to help support patients during episodes of heightened discomfort and assist with maintaining functional stability throughout the body.

---

Quick Fact: Support for Therapeutic Management
Kanjinti is applied across various clinical scenarios where supportive relief is needed to address the symptoms related to systemic imbalance and the risk of episodic changes associated with the condition.

Regulatory References

1. Trastuzumab therapeutic overview - NCI

Kanjinti (trastuzumab-anns) eligibility is governed by official regulatory criteria, focusing on absolute contraindications and pre-existing medical conditions.

Contraindications and Exclusions

Classification	Exclusion Criteria (Must NOT Use)
Absolute Contraindication	Known hypersensitivity to trastuzumab, murine proteins, or any excipients.
Severe Respiratory Status	Advanced malignancy causing severe dyspnea at rest or requiring supplementary oxygen.
Pregnancy Status	Pregnancy is prohibited due to the risk of fetal harm, including oligohydramnios and neonatal death.

Eligibility Conditions and Restrictions

Use of Kanjinti is conditional and requires strict monitoring for all patients, particularly those with pre-existing risks.

• Cardiac Function: Treatment requires mandatory pre-assessment and continuous monitoring of Left Ventricular Ejection Fraction (LVEF). Treatment must be withheld or permanently discontinued for a clinically significant decrease in LVEF.
• Reproductive Potential: Females must use effective contraception during treatment and for a minimum of 7 months following the final dose.
• Age Groups: The medication is established for adult patients. Relevant use in the pediatric population is not established in official labeling. Caution is advised for older adults due to a potentially increased cardiac risk.

Kanjinti Interactions with other medicines and products

Official regulatory documents define the interaction profile of Kanjinti (trastuzumab-anns) based primarily on pharmacodynamic risk and specific co-administration restrictions. As a large biologic medicine, its pharmacokinetic profile is not based on metabolism by Cytochrome P450 (CYP) enzymes, a common source of drug interactions for small-molecule drugs.

Classification	Interacting Agents / Context	Official Regulatory Statement
Pharmacodynamic Risk	Anthracycline-containing regimens	Co-administration is documented to result in the highest incidence and severity of Cardiomyopathy (cardiac failure) [FDA].
Combination Restriction	Ado-trastuzumab emtansine (T-DM1)	The label explicitly states: Do not substitute KANJINTI for or with ado-trastuzumab emtansine [FDA].
Non-Recommended Use	Live Vaccines	Co-administration with certain Live Vaccines is officially not recommended (e.g., Measles, Mumps, Rubella) [FDA].
Other Interactions	Warfarin	Use with this medicine may cause an increased risk of certain side effects [FDA].

Population-Specific Interaction Notes

The most stringent interaction note concerns reproductive risk: Exposure during pregnancy or within 7 months prior to conception can result in Embryo-Fetal Toxicity (e.g., oligohydramnios and neonatal death). Consequently, effective contraception must be used during treatment and for the following seven months by females of reproductive potential. The official label also notes that use with alcohol and tobacco may cause interactions to occur.

How Kanjinti Works

Kanjinti's mechanism of action involves a dual engagement of the Human Epidermal growth factor Receptor 2 ( HER2) protein and the innate immune system. Its activity is strictly dependent on the presence of the HER2 protein on the cell surface.

1. Inhibition of HER2-Mediated Signal Transduction

The active ingredient, trastuzumab-anns, binds with high affinity to the extracellular domain of the HER2 receptor. This binding sterically prevents receptor dimerization (pairing), a necessary step for activation. By blocking dimerization, the drug prevents the receptor's internal tyrosine kinase domain from propagating signals through key intracellular pathways, including the PI3K/ Akt and MAPK cascades. This signal disruption is correlated with the physiological consequences of decreased cellular proliferation rates and apoptosis induction (programmed cell death).

2. Antibody-Dependent Cellular Cytotoxicity ( ADCC)

As an IgG1 antibody, Kanjinti also initiates the ADCC mechanism. Once bound to HER2 on the target cell, the antibody's Fc fragment acts as a binding site for Fc receptors ( Fcgamma R) on immune effector cells, such as Natural Killer ( NK) cells. The immune cell is triggered to release lytic molecules that initiate the cellular lysis process in the antibody-coated cell. This ADCC mechanism results in the NK cell-mediated lysis of the target cell population.

Functional constraints occur when cells activate alternative signaling pathways or when the HER2 receptor is altered (e.g., truncation), preventing antibody binding.

Kanjinti is a medicine whose administration is strictly controlled by official regulatory guidelines, defining its route, dosage, frequency, and duration of use. Its purpose is to adhere to a standardized protocol established by government health authorities.

Administration and Dosage Principles

Kanjinti is approved for administration exclusively via intravenous (IV) infusion; it must not be given as a rapid injection or bolus. The medicine is supplied as a lyophilized powder and requires professional reconstitution and dilution before it can be infused. Standard dosing is determined by body weight, calculated in milligrams per kilogram (mg/kg), which differentiates between the initial loading dose and subsequent maintenance doses.

Schedule and Duration Patterns

The standard administration schedules involve either a weekly or a three-weekly (Q3W) cycle, with the maintenance dose continuing the chosen frequency. The duration of treatment varies depending on the use context. For early-stage disease, administration is typically maintained for a fixed period, often up to one year. In contrast, for advanced or metastatic disease, Kanjinti is generally continued until disease progression occurs.

Procedural Requirements

Administration must take place in a medically supervised setting, such as a hospital or clinic. The initial loading dose is required to be administered over 90 minutes, with subsequent maintenance doses taking a shorter duration, often 30 minutes, provided the earlier infusion was well tolerated. The preparation process specifically prohibits the use of dextrose (glucose) solution for dilution. If a dose is missed, specific, standardized rules govern whether a maintenance dose or a repeat loading dose is necessary to re-establish the correct cycle.

Research Evidence / Overview of Studies for Kanjinti

Evidence for Use in Early Breast Cancer (EBC)

The research for Kanjinti was primarily conducted through comparative clinical trials in adults diagnosed with HER2-overexpressing early breast cancer. These studies were randomized, meaning patients were assigned to receive either Kanjinti or the reference drug as part of a trial designed to demonstrate biosimilarity. The research was relevant in trials assessing short-term outcomes, particularly when Kanjinti was applied for evaluation in the neoadjuvant setting (before surgery).

In these comparative trials, the main outcome measured was the Pathologic Complete Response (pCR), which describes the absence of residual invasive cancer cells found after the evaluation. Studies monitored pCR rates, Pharmacokinetics, and Immunogenicity. Findings describe patterns observed in the studies showing that Kanjinti reported measurements of pCR that fell within the pre-specified equivalence margins, and data show patterns related to similarity to the reference product. The evidence contributes to the broader evidence landscape of the reference product.

---

Evidence for Use in Metastatic Breast Cancer (MBC)

Kanjinti was studied for use in metastatic breast cancer. No new, dedicated, large-scale Phase III clinical trial was conducted for Kanjinti specifically in this population. Instead, the evidence relies on a comprehensive scientific assessment that demonstrated its analytical, functional, and pharmacokinetic similarity to the reference product. This process is called extrapolation, where the demonstrated similarity in the early breast cancer study provides the basis for its application in other approved uses of the reference product.

Evidence for Use in Metastatic Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma

Similar to metastatic breast cancer, Kanjinti was evaluated in the context of advanced gastric or gastroesophageal junction adenocarcinoma using the principle of scientific extrapolation. This application relies on the scientific findings that Kanjinti's data show patterns related to similarity to the reference product, combined with the established evidence of the reference product in these conditions. The core research examined outcomes related to Overall Survival (OS) and Progression-Free Survival (PFS) from the reference product's Phase III trials.

---

Research Gaps and Remaining Uncertainties

A primary limitation is that Kanjinti's evaluation for metastatic breast cancer and GEJ cancer relies heavily on the scientific principle of extrapolation. This means that dedicated Phase III efficacy trials, which would re-evaluate long-term outcomes for Kanjinti in these specific populations, were not conducted. The long-term effects of Kanjinti itself are not fully established from dedicated, multi-year, comparative trials, and data for certain special groups remain insufficient.

Key Studies & References

1. Trastuzumab: NCI Drug Information

Common questions about Kanjinti (FAQ)

Q: What are the main benefits of taking Kanjinti for cancer?

A: Regulatory documents and studies indicate that Kanjinti has been shown to reduce the risk of cancer recurrence in patients with early-stage disease. It is also associated with improved clinical outcomes, such as Overall Survival (OS) and Progression-Free Survival (PFS), in metastatic disease. Kanjinti’s purpose is to act as a targeted therapy against HER2-positive tumors.

Q: Is it normal to feel really tired after getting Kanjinti?

A: Yes, fatigue is listed as a commonly reported adverse reaction in the official prescribing information for Kanjinti. Feeling tired or experiencing low energy is a frequent side effect reported by patients receiving this treatment.

Q: What are the most common side effects people report while on Kanjinti?

A: According to regulatory documents, the most common side effects reported in clinical studies (occurring in 10% or more of patients) often include fever, nausea, vomiting, and diarrhea. Other frequently reported reactions are headache, infections, increased cough, and fatigue.

Q: Can Kanjinti cause long-term side effects?

A: Kanjinti carries a Boxed Warning regarding the potential for Cardiomyopathy (heart failure), which is a serious safety risk. This heart problem can sometimes occur during or after the end of treatment. Due to this risk, official labeling requires the careful and ongoing monitoring of heart function before and during the treatment course.

Q: Does Kanjinti make your hair fall out?

A: While hair loss (alopecia) may not be frequently listed for Kanjinti alone, it is a common side effect of the other chemotherapy treatments that are often administered along with it. This side effect is typically associated with the overall regimen rather than Kanjinti specifically.

Q: Can I drink alcohol while I am receiving Kanjinti?

A: The official drug label notes that the use of alcohol may cause interactions to occur with Kanjinti. Consultation with a healthcare provider is generally recommended to understand how alcohol consumption may relate to an individual's treatment plan.

Q: Can older people/seniors receive Kanjinti treatment safely?

A: Kanjinti is established for use in adult patients, and clinical experience includes individuals who are 65 years and older. Official guidance recommends caution for older adults due to a potentially increased cardiac risk, meaning heart function must be closely monitored for all patients.

Q: Can I get the flu shot or other vaccines while on Kanjinti?

A: Regulatory information states that co-administration with Live Vaccines is officially not recommended. Consultation with a healthcare team is generally recommended regarding the use of inactivated or non-live vaccines, such as the flu shot, during treatment.

Q: How is Kanjinti different from Herceptin (trastuzumab)?

A: Kanjinti (trastuzumab-anns) is approved as a biosimilar to the reference product, Herceptin (trastuzumab). This means regulatory bodies have confirmed that Kanjinti is highly similar to Herceptin and has no clinically meaningful differences in terms of safety or effectiveness.

Q: What happens if I miss an appointment for my Kanjinti infusion?

A: If a dose of Kanjinti is missed or delayed, there are specific, standardized rules that govern whether a standard maintenance dose or a repeat loading dose is required to resume the correct schedule. Contacting the healthcare team immediately is necessary to determine the appropriate next steps for a missed dose.

Q: What should I do if I get a fever after my Kanjinti infusion?

A: Fever, chills, and headache are listed as potential signs of an infusion reaction. Patients are advised to promptly report any fever or concerning symptoms after an infusion so the healthcare team can perform an evaluation and provide appropriate care.

Q: Does Kanjinti interact with birth control pills?

A: Kanjinti carries a warning for fetal harm if exposure occurs during pregnancy, making effective contraception mandatory during treatment and for seven months after the final dose. Due to the critical need to prevent pregnancy, a discussion with a healthcare provider about the most effective birth control method is essential.

Q: Why do doctors prescribe Kanjinti instead of the original drug?

A: Kanjinti is approved as a biosimilar, meaning it has been proven to have no clinically meaningful differences from the original product in terms of safety and efficacy. Healthcare providers may prescribe it based on its comparable clinical performance, as well as considerations related to local availability and cost.

Q: Does Kanjinti cause headaches or joint pain?

A: Headache is listed in the official documents as a common adverse reaction. Official labeling for products containing the active ingredient, trastuzumab, also notes muscle or joint pain (arthralgia) as a possible side effect.

How to Store and Dispose of Kanjinti

Kanjinti (trastuzumab-anns) requires strict adherence to official storage requirements to maintain its stability.

Storage Requirements

The unopened vial must be stored under refrigeration at 2 C to 8 C (36 F to 46 F). The product must not be frozen at any time. To protect the medicine from light, it must be kept in the original outer carton.

Product State	Temperature Range	Maximum Duration
Reconstituted (BWFI)	2 C to 8 C	28 days
Reconstituted (SWFI)	N/A	Use immediately
Diluted (in IV Bag)	2 C to 8 C	24 hours

Disposal and Child Safety

Kanjinti must be kept out of the sight and reach of children. Unused or expired product and related waste must be disposed of according to local requirements. Do not dispose of this medicine in household waste or down the drain.